Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
FLAMINGO 研究 96 周结果显示，对于初治 HIV-1 感染者，每日一次的多替拉韦优于每日一次的达芦那韦/利托那韦。
期刊:Journal of the International Aids Society
影响因子:4.9
doi:10.7448/IAS.17.4.19490
Molina, Jean-Michel; Clotet, Bonaventura; van Lunzen, Jan; Lazzarin, Adriano; Cavassini, Matthias; Henry, Keith; Kulagin, Valeriv; Givens, Naomi; Brennan, Clare; de Oliveira, Carlos Fernando
